can semaglutide cause afib Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation | Cardiovascular Diabetology Semaglutide for the prevention of

After removing three duplicates, a total of two articles were screened

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that has revolutionized obesity treatment

Commonly reported (mild) Mild headache, usually short-lived

Mild Side Effects These side effects are reported anecdotally and tend to resolve on their own within a few days of use or dose adjustment: Headache or light-headedness Mild nausea or upset stomach (especially with oral use) Fatigue or lethargy in the first few days of use Appetite changes (increase or decrease) Injection site irritation redness, swelling, or tenderness Mild dizziness, nausea, and local irritation are among the most commonly reported side effects of subcutaneous BPC-157 injection, typically resolving within 2472 hours. Milekic, T